Steven Knapper

5.7k total citations · 1 hit paper
91 papers, 2.4k citations indexed

About

Steven Knapper is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Steven Knapper has authored 91 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Hematology, 39 papers in Genetics and 37 papers in Molecular Biology. Recurrent topics in Steven Knapper's work include Acute Myeloid Leukemia Research (62 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Steven Knapper is often cited by papers focused on Acute Myeloid Leukemia Research (62 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers) and Chronic Myeloid Leukemia Treatments (23 papers). Steven Knapper collaborates with scholars based in United Kingdom, United States and Denmark. Steven Knapper's co-authors include Alan K. Burnett, Mark J. Levis, Richard E. Clark, Donald Small, Robert K. Hills, Nigel H. Russell, Mary Frances McMullin, Amanda Gilkes, Raj Chopra and William J. Kell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Steven Knapper

86 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

2015 346 citations Alan K. Burnett, Nigel H. Russell et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Knapper United Kingdom	23	1.7k	1.2k	825	323	286	91	2.4k
Florian H. Heidel Germany	30	1.8k 1.0×	1.7k 1.4×	995 1.2×	268 0.8×	509 1.8×	143	3.1k
Mario Tiribelli Italy	25	1.3k 0.7×	656 0.6×	922 1.1×	277 0.9×	610 2.1×	97	2.2k
Susan O’Brien United States	29	2.2k 1.3×	949 0.8×	1.3k 1.5×	686 2.1×	575 2.0×	69	3.1k
Maximilian Stahl United States	25	1.3k 0.7×	970 0.8×	387 0.5×	236 0.7×	466 1.6×	121	2.0k
Jan Samuelsson Sweden	26	1.9k 1.1×	1.2k 1.0×	1.9k 2.3×	113 0.3×	271 0.9×	75	2.8k
Josef Thaler Austria	24	599 0.4×	593 0.5×	433 0.5×	116 0.4×	885 3.1×	108	2.0k
H. Jean Khoury United States	30	2.8k 1.7×	789 0.7×	2.3k 2.7×	358 1.1×	570 2.0×	117	3.7k
Steven Novick United States	16	645 0.4×	819 0.7×	362 0.4×	67 0.2×	437 1.5×	28	1.4k
Peter Gimsing Denmark	31	2.1k 1.2×	1.9k 1.6×	301 0.4×	90 0.3×	1.4k 5.0×	111	3.1k
Sabine Käyser Germany	23	2.2k 1.3×	1.4k 1.2×	770 0.9×	545 1.7×	366 1.3×	64	3.1k

Countries citing papers authored by Steven Knapper

Since Specialization

Citations

This map shows the geographic impact of Steven Knapper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Knapper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Knapper more than expected).

Fields of papers citing papers by Steven Knapper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Knapper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Knapper. The network helps show where Steven Knapper may publish in the future.

Co-authorship network of co-authors of Steven Knapper

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Knapper. A scholar is included among the top collaborators of Steven Knapper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Knapper. Steven Knapper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russell, Nigel H., Jad Othman, Oliver Cumming, et al.. (2025). Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML. Blood Advances. 9(24). 6455–6466.

Mehta, Priyanka, Nick Telford, Richard Dillon, et al.. (2022). Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology. 200(2). 150–159. 4 indexed citations

Mussai, Francis, Carmela De Santo, Paul Cheng, et al.. (2022). A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial. British Journal of Haematology. 200(5). 573–578. 7 indexed citations

Nicholson, R.I., Ana Catarina Menezes, Claire Seedhouse, et al.. (2022). Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux. Frontiers in Oncology. 12. 840046–840046. 8 indexed citations

Russell, Nigel H., Charlotte S. Wilhelm-Benartzi, Steven Knapper, et al.. (2022). FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial. Blood. 140(Supplement 1). 526–528. 4 indexed citations

Dillon, Richard, Aimee Jackson, Sonia Fox, et al.. (2022). Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer. 22(1). 1174–1174. 2 indexed citations

Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2020). Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of Clinical Oncology. 39(8). 890–901. 19 indexed citations

Milne, Paul, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, et al.. (2019). Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances. 3(20). 3052–3061. 17 indexed citations

McMullin, Mary Frances, Claire Harrison, Catherine Cargo, et al.. (2018). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology. 184(2). 176–191. 94 indexed citations

10.

McMullin, Mary Frances, Adam J. Mead, Sahra Ali, et al.. (2018). A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis. British Journal of Haematology. 184(2). 161–175. 70 indexed citations

11.

Drummond, Mark W., Claire Harrison, Adam J. Mead, et al.. (2017). A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG). Blood. 130. 1649–1649. 2 indexed citations

12.

Butt, Nauman M., Jonathan Lambert, Sahra Ali, et al.. (2017). Guideline for the investigation and management of eosinophilia. British Journal of Haematology. 176(4). 553–572. 83 indexed citations

13.

Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2015). Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 16(13). 1295–1305. 346 indexed citations breakdown →

14.

Mead, Adam J., Dragana Milojković, Steven Knapper, et al.. (2013). Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial. Blood. 122(21). 2826–2826. 5 indexed citations

15.

Reilly, John T., Mary Frances McMullin, Philip Beer, et al.. (2012). Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology. 158(4). 453–471. 71 indexed citations

16.

Walsby, Elisabeth, Steven Coles, Steven Knapper, & Alan K. Burnett. (2010). The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 96(3). 393–399. 45 indexed citations

17.

Szegezdi, Éva, Carlos R. Reis, Almer M. van der Sloot, et al.. (2010). Targeting AML through DR4 with a novel variant of rhTRAIL. Journal of Cellular and Molecular Medicine. 15(10). 2216–2231. 19 indexed citations

18.

Moore, Catherine, Mónica Galiano, Angie Lackenby, et al.. (2010). Evidence of Person-to-Person Transmission of Oseltamivir-Resistant Pandemic Influenza A(H1N1) 2009 Virus in a Hematology Unit. The Journal of Infectious Diseases. 203(1). 18–24. 50 indexed citations

19.

Hewamana, Saman, et al.. (2008). IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. International Journal of Hematology. 88(4). 424–427. 2 indexed citations

20.

Knapper, Steven. (2007). FLT3 inhibition in acute myeloid leukaemia. British Journal of Haematology. 138(6). 687–699. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact